Sign in
WithdrawnPhase 4

Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications

Key facts

Who runs it
University of Wisconsin, Madison
Where
Baltimore, Chapel Hill, Jacksonville, Madison, Nashville, and New York, United StatesSee the 6 sites
Trial code
Status
Withdrawn
Phase
Phase 4
Started
Oct 2024
Expected to end
Sept 2027
Type of study
Interventional
Treatments tested
  • Adjuvanted Recombinant Zoster Vaccine (RZV)
Record updated
25 September 2024
Why it stopped
Funding ended

Who can take part

Age
19 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patient is between the ages of 19 and 85 years with a diagnosis of IBD based on standard clinical and histological criteria
  • Can provide appropriate written informed consent
  • Patient has a history of ulcerative colitis or Crohn's disease diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria
  • Patient is receiving one of the following treatments for their IBD:; Anti-TNF therapy (infliximab, adalimumab, certolizumab, or golimumab); On anti-TNF monotherapy; Or anti-TNF therapy in combination with either 10mg of methotrexate or azathioprine at least 1.0mg/kg or 6-Mercaptopurine (6MP) 0.5mg/kg; Non-TNF therapy; On ustekinumab monotherapy or in combination with either 10mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg; On vedolizumab monotherapy or in combination with either 10mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg; On Risankizumab monotherapy or in combination with either 10mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg; On mirikizumab monotherapy or in combination with either 10mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg; Janus Kinase Inhibitor; On tofacitinib at least 5mg PO twice per day (BID); On upadactinib at least 15mg PO BID
  • Patient has been on stable biologic or JAK treatment for IBD for at least two months
  • Patient is in stable clinical remission; o No recent corticosteroid prescription within the past two months
  • Female participant of non-childbearing potential (pre-menarche, current tubal ligation, hysterectomy, oophorectomy or post-menopause) and childbearing potential (if they had: practiced adequate contraception (include IUD or equivalent, hormonal contraceptive (e.g. pill, patch, ring, implant or an injection used consistently and that has reached full effect prior to the first dose of vaccine), hysterectomy and/or a bilateral tubal ligation or bilateral oophorectomy) for 1 month prior to vaccination and agrees to continue adequate contraception during the primary treatment period, and for 2 months after completion of the vaccination series). Non-pregnant females with a negative pregnancy test who are willing to practice adequate contraception during the primary treatment period, and for 2 months after completion of the vaccination series)

Who cannot take part

  • Patient has been taking any dose of oral or intravenous steroids for more than 3 days within 2 months prior to immunization
  • Previous vaccination against HZ or varicella within the 12M preceding the first dose of RZV
  • Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to the use of induction and/or maintenance immunosuppressive therapies
  • Any confirmed or suspected HIV, primary immunodeficiency disease, disseminated or untreated malignancy, or systemic infection
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or study material and equipment
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe
  • Patient cannot or will not provide written informed consent
  • Occurrence of varicella or HZ per clinical history, within the 12M preceding the first dose of RZV
  • Pregnant or lactating female
  • Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 3 (i.e. 2 months after last dose of study V2)

Where in United States

  • Mercy Medical CenterBaltimore, United States
  • University of North CarolinaChapel Hill, United States
  • Mayo ClinicJacksonville, United States
  • UW Hospital and ClinicsMadison, United States
  • Vanderbilt UniversityNashville, United States
  • New York UniversityNew York, United States

About the trial

What the trial wants to find out

This multi-center study will evaluate the safety and immune response to recombinant zoster vaccine (RZV) series in 264 patients with inflammatory bowel disease (IBD) on immunosuppressive therapy recruited from 6 study sites who can expect to be on study for up to 14 months.

The group in the trial

  • Adults with IBDTreatment being tested

    Treatment: Adjuvanted Recombinant Zoster Vaccine (RZV)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Inflammatory Bowel Disease on Biologic Immunosuppressive Therapies
Record updated
25 September 2024